IPP Bureau
Supriya Lifescience names Dr. Saloni Wagh as MD
By IPP Bureau - August 03, 2024
Shivani Satish Wagh takes on the role of Joint Managing Director
Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
By IPP Bureau - August 03, 2024
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL
By IPP Bureau - August 03, 2024
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr
By IPP Bureau - August 02, 2024
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr
By IPP Bureau - August 02, 2024
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr
By IPP Bureau - August 02, 2024
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
By IPP Bureau - August 02, 2024
Strong topline growth driven by solid performance across key brands.
Shilpa Pharma Lifesciences received CEP from EDQM for ursodeoxycholic acid
By IPP Bureau - August 01, 2024
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
Lupin receives approval from USFDA for Emtricitabine and Tenofovir Alafenamide Tablets
By IPP Bureau - August 01, 2024
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control
By IPP Bureau - August 01, 2024
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr
By IPP Bureau - August 01, 2024
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Dr. Jitendra Singh conferred Lifetime Achievement Award
By IPP Bureau - August 01, 2024
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
Dr. Agarwals Eye Hospital posts standalone Q1 FY25 PAT higher at Rs. 14.11 Cr
By IPP Bureau - August 01, 2024
Dr. Agarwals Eye Hospital has reported total income of Rs. 100.42 crores during the period ended June 30, 2024
Ajanta Pharma posts Q1 FY25 consolidated PAT at Rs. 245.77 Cr
By IPP Bureau - August 01, 2024
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause
By IPP Bureau - August 01, 2024
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
